Successful Use of Infliximab Therapy in Sight-threatening Corticosteroid-resistant Vogt-Koyanagi-Harada Disease. (August 2013)

• Record Type: Journal Article
• Authors: Zmuda, Mathieu; Tiev, Kiet Phong; Knoeri, Juliette; Héron, Emmanuel
• Is Part Of: Ocular immunology and inflammation. Volume 21:Number 4(2013)
• Page Start: 310
• Page End: 316
• Publication Date: 2013-08
• Subjects: Eye -- Diseases -- Immunological aspects -- Periodicals; Eye -- Inflammation -- Periodicals; 617.7
• DOI: 10.3109/09273948.2013.775312
• Languages: English
• ISSNs: 0927-3948

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <p> <italic>Purpose</italic>: To report an experience with infliximab in severe corticosteroid-resistant Vogt-Koyanagi-Harada (VKH) disease.</p> <p> <italic>Design</italic>: Interventional case series.</p> <p> <italic>Methods</italic>: The medical records of 2 adult patients were reviewed.</p> <p> <italic>Results</italic>: Both patients had a visual acuity reduced to hand motion perception bilaterally after 1 month of high-dose corticosteroid therapy, due to multiple exudative retinal detachment involving the fovea. Visual acuity and OCT findings improved immediately after the first infliximab infusion, retinal detachments fully resolved after 1 month and visual acuity returned to normal within 6 months. Despite a negative pretreatment screening, one patient developed multivisceral tuberculosis, which led to infliximab discontinuation after the 7th infusion and was cured by a 9-month ambulatory antibiotic regimen. The other patient received 11 well-tolerated infliximab infusions. Respectively, 9 and 4 months after infliximab discontinuation both patients had normal vision and OCT findings.</p> <p> <italic>Conclusion</italic>: Infliximab showed tremendous therapeutic efficacy in sight-threatening corticosteroid-resistant VKH disease.</p> </abstract>